Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAcorda Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Acorda Therapeutics, Inc. Earnings Date And Information
Acorda Therapeutics, Inc. last posted its earnings results on Thursday, March 9th, 2023. The company reported $11.4 earnings per share for the quarter, topping analysts' consensus estimates of $-3 by $14.4. The company had revenue of 20.29 M for the quarter and had revenue of 117.63 M for the year. Acorda Therapeutics, Inc. has generated $-204 earnings per share over the last year ($-203.59 diluted earnings per share) and currently has a price-to-earnings ratio of -0. Acorda Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based on prior year's report dates.
Acorda Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/14/2024 | Q1 2024 | N/A | -$22.06 | N/A | $20.29 M | $20.29 M |
| 04/01/2024 | Q4 2023 | N/A | -$225.81 | N/A | $138.92 M | $37.99 M |
| 11/13/2023 | Q3 2023 | N/A | -$7.16 | N/A | N/A | $27.72 M |
| 08/08/2023 | Q2 2023 | N/A | -$7.55 | N/A | $27.79 M | $29.68 M |
| 05/11/2023 | Q1 2023 | N/A | -$13.83 | N/A | $19.36 M | $22.26 M |
| 03/14/2023 | Q4 2022 | N/A | $15.73 | N/A | $35.00 M | $31.47 M |
| 11/14/2022 | Q3 2022 | N/A | -$11.41 | N/A | $30.50 M | $33.51 M |
| 08/09/2022 | Q2 2022 | N/A | -$55.63 | N/A | $29.10 M | $31.05 M |
| 05/13/2022 | Q1 2022 | N/A | -$37.01 | N/A | $26.00 M | $22.53 M |
| 03/18/2022 | Q4 2021 | N/A | -$34.69 | N/A | $31.01 M | $36.97 M |
| 11/12/2021 | Q3 2021 | N/A | -$48.64 | N/A | $30.57 M | $31.46 M |
| 08/12/2021 | Q2 2021 | N/A | -$45.76 | N/A | $29.94 M | $31.79 M |
| 05/12/2021 | Q1 2021 | N/A | -$70.65 | N/A | $22.15 M | $28.86 M |
| 03/16/2021 | Q4 2020 | N/A | -$196.47 | N/A | $34.00 M | $38.16 M |
| 11/06/2020 | Q3 2020 | N/A | $18.46 | N/A | $29.47 M | $53.09 M |
| 08/07/2020 | Q2 2020 | N/A | -$43.77 | N/A | $27.40 M | $33.62 M |
| 05/08/2020 | Q1 2020 | N/A | -$16.26 | N/A | $41.01 M | $28.10 M |
| 02/28/2020 | Q4 2019 | N/A | $165.62 | N/A | $44.58 M | $50.50 M |
| 11/07/2019 | Q3 2019 | N/A | -$665.62 | N/A | $42.50 M | $47.72 M |
| 08/07/2019 | Q2 2019 | N/A | -$69.46 | N/A | $28.83 M | $50.05 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Acorda Therapeutics, Inc. Earnings: FAQ's
Acorda Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based offlast year's report dates.
In the previous quarter, Acorda Therapeutics, Inc. (:ACOR) reported $11.4 earnings per share (EPS) to beat the analysts' consensus estimate of $-3 by $14.4.
The conference call for Acorda Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Acorda Therapeutics, Inc.'s latest earnings report can be read online.
Acorda Therapeutics, Inc. (:ACOR) has a recorded annual revenue of $117.63 M.
Acorda Therapeutics, Inc. (:ACOR) has a recorded net income of $-252,854,000.Acorda Therapeutics, Inc. has generated $-203.59 earnings per share over the last four quarters.
Acorda Therapeutics, Inc. (:ACOR) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is 0.